Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Kirsehir Ahi Evran Universitesi
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07337135CT.gov Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery | — | Completed | — | — | — |
NCT05752799CT.gov Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids | — | Recruiting | — | — | — |
NCT02017314CT.gov VAS Correlation With BMI | — | Unknown | — | — | — |
NCT03809182CT.gov Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. | — | Completed | — | — | — |
NCT01249872CT.gov Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morbid Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nepenthe (this asset) | Kirsehir Ahi Evran Universitesi | Approved | BB · 69 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Colesevelam | Hvidovre University Hospital | P4 | BBB |
| Chenodeoxycholic Acid | Hvidovre University Hospital | P4 | BBB |
| Ramifentanyl | Hospital dos Lusíadas | P4 | BBB |
| Propofol | G.Gennimatas General Hospital | P4 | BBB |
| Amoxicillin | Fatih Sultan Mehmet Training and Research Hospital | P4 | BBB |
| Semaglutide | Zuyderland Medisch Centrum | P4 | BBB |
| Omeprazole | Fatih Sultan Mehmet Training and Research Hospital | P4 | BB |
+42 more in the Morbid Obesity cohort
Other indications for Nepenthe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nepenthe in Morbid Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nepenthe-morbid-obesity-25392
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →